Alexei Kharitonenkov
Overview
Explore the profile of Alexei Kharitonenkov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
7874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li X, Lu W, Kharitonenkov A, Luo Y
J Intern Med
. 2024 Jan;
295(3):292-312.
PMID: 38212977
Human fibroblast growth factor 19 (FGF19, or FGF15 in rodents) plays a central role in controlling bile acid (BA) synthesis through a negative feedback mechanism. This process involves a postprandial...
2.
Zhang Y, Zhao X, Dong X, Zhang Y, Zou H, Jin Y, et al.
Cell Metab
. 2023 Jan;
35(2):287-298.e4.
PMID: 36706758
Obesity is a considerable health concern with limited pharmacotherapy options of low efficacy. Here, we develop a GLP-1/GDF15 fusion protein and explore its weight-lowering potential in animals. The molecule, QL1005,...
3.
Yang R, Xu A, Kharitonenkov A
J Clin Endocrinol Metab
. 2021 Sep;
107(1):e417-e419.
PMID: 34529079
No abstract available.
4.
Nason S, Antipenko J, Presedo N, Cunningham S, Pierre T, Kim T, et al.
JCI Insight
. 2021 Jan;
6(4).
PMID: 33411693
Glucagon regulates glucose and lipid metabolism and promotes weight loss. Thus, therapeutics stimulating glucagon receptor (GCGR) signaling are promising for obesity treatment; however, the underlying mechanism(s) have yet to be...
5.
Talukdar S, Kharitonenkov A
Mol Metab
. 2020 Dec;
46:101152.
PMID: 33383173
Objective: FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog...
6.
Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21
Pan J, Parlee S, Brunel F, Li P, Lu W, Perez-Tilve D, et al.
ACS Pharmacol Transl Sci
. 2020 Oct;
3(5):978-986.
PMID: 33073195
Fibroblast growth factors 19 and 21 (FGF19 and FGF21) have biological actions that render them promising clinical candidates for treatment of metabolic diseases, particularly dyslipidemia and nonalcoholic steatohepatitis (NASH). These...
7.
Wu S, Grunwald T, Kharitonenkov A, Dam J, Jockers R, De Luca F
J Biol Chem
. 2020 Sep;
295(37):13137.
PMID: 32917830
No abstract available.
8.
Agrawal A, Parlee S, Perez-Tilve D, Li P, Pan J, Mroz P, et al.
Mol Metab
. 2018 May;
13:45-55.
PMID: 29789271
Objective: To signal, FGF19 and FGF21 require co-receptor βKlotho (KLB) to act in concert with FGF receptors, and yet there is appreciable variance in the C-terminal sequences of these two...
9.
Ippagunta S, Kharitonenkov A, Adams A, Hillgartner F
J Nutr
. 2018 Apr;
148(4):510-517.
PMID: 29659970
Background: Supplementation of a high-fat obesogenic diet (HFD) with cholic acid (CA) suppresses the development of obesity, insulin resistance, and hepatic steatosis in mice. Objective: We investigated the role of...
10.
Sanchez-Garrido M, Habegger K, Clemmensen C, Holleman C, Muller T, Perez-Tilve D, et al.
Mol Metab
. 2016 Oct;
5(10):1015-1024.
PMID: 27689014
Objective: Fibroblast activation protein (FAP) is a serine protease belonging to a S9B prolyl oligopeptidase subfamily. This enzyme has been implicated in cancer development and recently reported to regulate degradation...